Gracillin CAS 19083-00-2 Spirostanol Saponin from Dioscoreaspp
Product Identification
| Item | Detail |
|---|---|
| Synonyms | Gracillin; Diosgenin 3-O-β-gracillimatrioside; Dulcamarin C; Lilioglycoside G; NSC 698787 |
| CAS RN | 19083-00-2 |
| Aglycone (downstream) | Diosgenin 512-04-9 (acid hydrolysis product, same as Dioscin) |
| Sibling (same plant, same aglycone) | Dioscin CAS 19057-60-4 (chacotriose, 2 Rha+1 Glc, C₄₅H₇₂O₁₆, 869) |
| Molecular Formula | C₄₅H₇₂O₁₇ |
| MW | 885.04 |
| Botanical (named for) | Dioscorea gracillimaHemsl. (纤细薯蓣) |
| Botanical (commercial co-extract) | D. zingiberensis(黄姜, main), D. nipponica(穿龙), D. opposita(山药, trace) |
| HS Code (ref) | 1302 / 2938 |
| Ref standard (example) | Sigma PHL83503 (PhytoLab phyproof, ≥95%, 10 mg) |
Description
Gracillin is the minor trisaccharide spirostanol saponin of Dioscorearhizomes, co-extracted alongside the major Dioscin. Three commercial angles (all lean R&D/QC, not bulk like Dioscin):
- B2B “Dioscin Co-Peak” QC (main commercial lane for Gracillin): D. zingiberensisalkali-EtOH extract → HPLC shows Dioscin main peak + Gracillin minor peak eluting slightly earlier (Rha-Glc-Glc vs Rha-Rha-Glc retention diff). Buyers of “huang-jiang P.E. Dioscin%” often ask: “What’s the small peak before Dioscin? Should I report it?”→ Gracillin. Taima: pure Gracillin 98%+ as reference standard for DioscoreaP.E. QC labs (to confirm co-peak identity, quantify if needed). Also “Dioscin + Gracillin dual-peak” bundle quote: Dioscin P.E. (10–80%) + Gracillin 98% ref (10–100 mg). Search: “Gracillin Dioscin co-peak HPLC”, “Dioscorea zingiberensis minor saponin”, “huang-jiang extract dual-peak”
- R&D SAR / Antitumor Compare (R&D lane): Gracillin literature on HepG2, A549, SGC-7901, HeLa — Bcl-2/Bax, caspase-3/9, ROS, PI3K/Akt — but consistently weaker than Dioscin (BenchChem 2025: chacotriose Dioscin >> non-chacotriose Gracillin in HeLa/H7402 MTT). R&D use-case: (a) SAR control (“chacotriose vs. Rha-Glc-Glc trisaccharide” on same aglycone), (b) comparison to Dioscin for formulation pilot where “lower potency but different PK/solubility” matters, (c) co-formulation “Dioscin + Gracillin” mimicking native P.E. profile.
Applications
B2B QC “Dioscin Co-Peak” Reference – Gracillin ≥98% as reference standard for D. zingiberensis/ D. nipponicaP.E. HPLC (Dioscin main + Gracillin minor dual-peak ID); “huang-jiang extract QC” B2B; bundle: Dioscin P.E. 10–80% + Gracillin 98% ref 10–100 mg
R&D SAR / Antitumor Compare – Gracillin vs Dioscin 98% duo for “chacotriose (Rha-Rha-Glc) vs non-chacotriose (Rha-Glc-Glc) on same aglycone (diosgenin)” SAR; HepG2/A549/SGC-7901 lit (weaker than Dioscin, BenchChem 2025); co-formulation “native Dioscorea profile” pilot
Acid Hydrolysis → Diosgenin (theoretical, not economical) – Gracillin 98% → diosgenin + Rha + 2×Glc; redirect PO “steroid precursor” to Dioscin P.E. or Diosgenin 512-04-9; Gracillin 98% not industrial steroid route (yield low, price high)
Reference Standard (≥98%) – for DioscoreaP.E. dual-peak QC, SAR libraries, CRO “spirostanol saponin” panel; pack size 5 mg / 10 mg / 25 mg / 100 mg
